Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Headline
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…
Headline
The U.S. District Court for the Southern District of Florida March 6 ruled in favor of five Florida hospitals in a case challenging the methodology used by the…
Headline
The Centers for Disease Control and Prevention Feb. 26 announced that an infant botulism outbreak that sickened 48 babies who consumed ByHeart formula is over…
Headline
The measles outbreak in South Carolina has increased to 876 cases, the state’s Department of Public Health reported Feb. 3. Last week, the South Carolina…
Headline
Thomas McGinn, M.D., senior executive vice president and chief physician executive officer at CommonSpirit Health, shares how the organization aligns…
Headline
The Centers for Disease Control and Prevention released its annual progress report on health care-associated infections Jan. 29, which found continued…